SUCCINYLCHOLINE CHLORIDE

Post-LOE

succinylcholine chloride

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

Feb 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

SUCCINYLCHOLINE CHLORIDE (succinylcholine chloride) by Fresenius Kabi is blocker. Approved for mechanical ventilation. First approved in 2023.

Drug data last refreshed 18h ago

Mechanism of Action

blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the…

Indications (1)

mechanical ventilation

Worked on SUCCINYLCHOLINE CHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.